Cancer immunotherapy and biotechnology by Arcus Biosciences

  • Sergey Shendetskyi
  • 20.10.2026
Arcus Biosciences stock holds steady as new ARC-20 kidney cancer data
Arcus Biosciences announced on September 23, 2026, new data from its ARC-20 platform study demonstrating promising results for its kidney cancer therapy. Separately, the stock is little changed on ...
  • Ashutosh Sureka
  • 05.08.2026
Arcus Biosciences stock drops 3.8 percent to $27.70 as price tests support below MA-20
Arcus Biosciences has announced its second-quarter financial results and provided an update on its clinical-stage pipeline. At the same time, Arcus Biosciences stock is down 3.8% on the day at ...
  • Ashutosh Sureka
  • 05.08.2026
Arcus Biosciences stock under pressure after losing key support, upside likely if $28.38 recaptured
Arcus Biosciences posted an update on its second-quarter financial results and clinical-stage pipeline through its official account. At the same time, Arcus Biosciences stock is down 3.8% on the ...
  • Jose Antonio Gastelum
  • 23.07.2026
Arcus Biosciences stock rises 1.66% after arcusbio announces AVEO Oncology clinical study partnership
Arcus Biosciences announced a clinical supply agreement with AVEO Oncology to evaluate casdatifan in combination with a VEGFR tyrosine kinase inhibitor.The companies will conduct the evaluation in ...
  • Sholanke Dele
  • 23.07.2026
Arcus Biosciences stock edges higher to $29.97 after new clinical partnership announcement
Arcus Biosciences announced a clinical supply agreement with AVEO Oncology. The agreement will evaluate casdatifan, Arcus Biosciences' investigational HIF-2α inhibitor, in combination with a ...
  • Jose Antonio Gastelum
  • 02.07.2026
Arcus Biosciences stock extends recent pullback as technical signals favor stabilization
Arcus Biosciences celebrated its recent recognition on the New York Stock Exchange trading floor. The company acknowledged its team's achievements following the publication of ARC-20 trial data in ...
  • Jose Antonio Gastelum
  • 02.07.2026
Arcus Biosciences stock drops 6.2% as ARC-20 trial data earns NYSE spotlight, arcusbio says
Arcus Biosciences saw its science recognized on the NYSE trading floor today. The company acknowledged the event, congratulating its team for a recent publication in Nature featuring ARC-20 trial ...
  • Ezequiel Gomes
  • 01.07.2026
Arcus Biosciences stock drops 2.43% as Nature publication highlights kidney cancer research, arcusbio says
Arcus Biosciences announced that data from its ARC-20 platform study are now published in Nature.The kidney cancer study is described as the first to comprehensively explore the connection between ...
  • Emilio Ghigini
  • 01.07.2026
Arcus Biosciences stock slips 2.43% as Nature-published kidney cancer data spurs profit taking, arcusbio reports
Arcus Biosciences announced that data from its ARC-20 platform study are now published in Nature.Arcus Biosciences said its kidney cancer study is the first to comprehensively explore the ...
  • Ashutosh Sureka
  • 03.06.2026
Arcus Biosciences stock drops 4.67% as Arcus Biosciences unveils BMS kidney cancer trial partnership
Arcus Biosciences announced a clinical trial collaboration and supply agreement with BMS to evaluate casdatifan in advanced kidney cancer.The agreement will test Arcus Biosciences' investigational ...
  • Ashutosh Sureka
  • 03.06.2026
Arcus Biosciences stock drops 4.67% as Arcus Biosciences announces BMS trial partnership
Arcus Biosciences announced a clinical trial collaboration and supply agreement with BMS to evaluate its investigational HIF-2a inhibitor, casdatifan.The agreement will test casdatifan in ...